Lapatinib Unknown Status Phase 1 Trials for Recurrent Endometrial Cancer Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01454479A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma